Belmont, MA - Individuals with major depressive disorder or bipolar disorder who receive low-field magnetic stimulation (LFMS) show immediate and substantial mood improvement, report McLean Hospital researchers in the August 1 issue of Biological Psychiatry.
“LFMS is unlike any current treatment. It uses magnetic fields that are a fraction of the strength but at a higher frequency than the electromagnetic fields used in TMS and ECT,” explained first author Michael Rohan, PhD, a physicist at McLean Hospital’s Brain Imaging Center and a lecturer at Harvard Medical School.
According to Rohan, although other brain stimulation treatments like electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS) are often effective for the treatment of depression, they typically take longer to have an impact on mood. In addition, in the case of ECT, it is associated with side effects, such as memory loss.
Likewise, antidepressant medications can be highly effective in treating depression but can take between four to six weeks before mood changes can be detected.
“Importantly, LFMS appears to have an immediate effect on mood and thus has the potential to provide relief in emergency situations,” explained Rohan, who first reported on the potential use of LFMS to treat depression in a ground-breaking study in 2004. “In addition to providing quick relief from symptoms, the other exciting piece about LFMS is that no side effects have been observed.”
Using a portable tabletop LFMS device that Rohan designed, the researchers conducted the study with 63 volunteers between the ages of 18 and 65. All participants were diagnosed with either major depressive disorder or bipolar disorder and were on a stable regimen of antidepressants or mood-stabilizing medications for at least six weeks. Of the study participants, 34 actively received LFMS, while the other 29 went through the process of receiving LFMS, but did not actually receive any brain stimulation. Since neither the patients nor the researchers knew which treatment each person actually received, the true effect of the LFMS could be measured.
Each participant rated their mood before and after the single 20-minute treatment of LFMS using two common self-assessment tools—a visual analog scale and the positive and negative affect schedule. The participants who actively received the LFMS treatment indicated a marked improvement in their mood, while those who did not receive LFMS reported no change in mood.
“We observed immediate improvement in mood following relatively brief exposure to LFMS,” noted Rohan. “Although larger research studies are needed, we think LFMS could be a powerful tool as a rapidly acting treatment for depression either alone or in combination with medication.”
Biological Psychiatry also published commentary from experts on brain stimulation who said Rohan’s work on LFMS is exciting and showed great promise.
“If the results described in this study are replicated in larger studies and the effects are shown to be durable, LFMS would be a welcome addition to the clinical armamentarium in the treatment of depression, may find application in other psychiatric and neurologic diseases, and may help to inform and guide us toward future directions in neuromodulation,” wrote Mouhsin Shafi, MD, Philip Stern, MD, and Alvaro Pascual-Leone, MD, PhD.
According to Rohan, additional research is already underway to find the best parameters for LFMS use in the clinical treatment of depression. He has also stated a research study to evaluate the effects of multiple compared to single treatments, and how long the antidepressant effects last following treatment.
McLean Hospital is the largest psychiatric affiliate of Harvard Medical School and a member of Partners HealthCare. For more information about McLean, visit mcleanhospital.org or follow the hospital on Facebook or Twitter.
Back to News